BioStem Technologies, Inc. 8K

BioStem Technologies reported Q2 2026 results with 29% sequential revenue growth, a $9.0 million net loss, completion of a Nasdaq Capital Market uplisting and $2.5 million private placement, debt restructuring, and a modest increase to full-year 2026 revenue guidance.

BioStem Technologies, Inc. reported its unaudited financial results for the quarter ended June 30, 2026, highlighting net revenue of $7.9 million (29% sequential growth but down from $11.0 million a year earlier), gross profit of $4.8 million at a 61% margin, operating expenses of $13.2 million and a GAAP net loss of $9.0 million, alongside an Adjusted EBITDA loss of $4.6 million. Operationally, the company continued scaling its commercial organization, integrated CRM and ERP systems, transitioned major GPO agreements, and expanded its IP with eight new U.S. design patents covering fenestrated human placental allograft technology. From a capital markets and balance sheet perspective, BioStem completed the uplisting of its common stock to the Nasdaq Capital Market on August 7, 2026, closed a $2.5 million private placement with its first institutional investor, and addressed $5.3 million of outstanding debt through a $3.5 million cash payment and issuance of a $1.0 million promissory note, ending the quarter with $7.0 million in cash and cash equivalents. Reflecting improved revenue trends, the company raised its full-year 2026 revenue guidance to a range of $26 million to $29 million (from $25 million to $29 million) and provided notice of a related earnings conference call and webcast.

Filing Facts

CIK

1658678

Ticker

-

Form

8K

Source Type

sec

Accession

0001193125-26-347211

Alert Tier

7